2019 Novel Coronavirus (COVID-19)

 COVID-19 Vaccination

Last Updated: May 20, 2022
​​​

Army Announces Implementation of Mandatory Vaccines for Soldiers

The Army has outlined its plan to fully comply with the Secretary of Defense’s order requiring all Service members to be fully vaccinated against COVID-19. Effective immediately, commanders will initiate involuntary administrative separation proceedings for Soldiers who have refused the lawful order to be vaccinated against COVID-19 and who do not have a pending or approved exemption request. Commands will process these separation actions, from initiation to a Soldier’s potential discharge, as expeditiously as possible. Soldiers with questions about the safety, effectiveness and possible side effects of the COVID-19 vaccine should discuss them with their health care provider. Read more hereExternal Link


MHS Immunization Healthcare - COVID-19 Vaccine ResourcesExternal Link

Risk Communication Strategy for Mandatory VaccinationExternal Link (milSuite CAC log-in required)

Secretary of the Army Memorandum - Army Directive 2022-02 (Personnel Actions for Active Duty Soldiers Who Refuse the COVID-19 Vaccination Order and Accession Requirements for Unvaccinated Individuals)External Link

Secretary of Defense Memorandum - Mandatory Coronavirus Disease 2019 Vaccination of Department of Defense Service Members, August 24, 2021External Link

Army Regulation 40-562, Immunizations and Chemoprophylaxis for the Prevention of Infectious Diseases External Link


Department of Defense 05 October 2021 guidance - Service members who are pregnant, postpartum and/or breastfeeding should be vaccinated as part of mandatory COVID-19 vaccination of DoD Service as they are not medically exempt from COVID-19 vaccination, unless they request and are qualified/approved for a temporary medical exemption from their health care provider.​

For information about the mandatory COVID-19 vaccine requirement for the federal workforce please check with your local human resources department or the Office of Personnel Management. The Safer Federal Workforce websiteExternal Link provides ongoing guidance to keep employees safe and agencies operational.


Everyone is encouraged to schedule their vaccine appointment now. 



Use the DHA Appointing Portal (DAP)External Link to schedule your COVID-19 vaccine appointment.

Book your vaccine today at your local military hospital or clinic!  Learn more at TRICARE.mil/DAPExternal Link

 

Vaccines.govExternal Link

Beneficiaries can also use Vaccines.govExternal Link to find state and local vaccination sites and retail pharmacies nearby, then call or visit their website to make an appointment.




Frequently Asked Questions

About the Vaccines

Eligibility

MHS COVID-19 Vaccine Resource Center for Healthcare Personnel

Communication Products and Educational Resources

General Resources

Frequently Asked Questions


About the Vacc​ines

As of 23 August, 2021; the FDA formally licensed the Pfizer-BioNTech COMIRNATY® COVID-19 vaccine. The FDA-approved COMIRNATY® vaccine is the same as the Pfizer-BioNTech vaccine that was administered under the FDA’s Emergency Use Authorization (EUA). The vaccine is –

  • approved to be administered in a two-dose series, 3 weeks apart, for the prevention of COVID-19 in individuals 16 years of age and older.
  • authorized under EUA to be administered to:
    • prevent COVID-19 in individuals 5 years of age and older.
    • ​provide a third dose at least 4 weeks after the second to immunocompromised individuals 5 years of age and older.
    • provide a single booster dose for individuals 12 years of age and older at least five months after completing a primary series of the vaccine.
    • provide a second booster dose to individuals 50 years of age and older at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine.
    • provide a second booster dose to individuals 12 years of age and older with certain kinds of immunocompromise at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine. These are people who have undergone solid organ transplantation, or who are living with conditions that are considered to have an equivalent level of immunocompromise.

As of 31 January, 2022; the FDA formally licensed the Moderna Spikevax COVID-19 vaccine. The FDA-approved Spikevax vaccine is the same as the Moderna vaccine that was administered under the FDA’s Emergency Use Authorization (EUA). The vaccine is –

  • approved to be administered in a two-dose series, 4 weeks apart, for the prevention of COVID-19 in individuals 18 years of age and older.
  • authorized under EUA to be administered to:
    • provide a third dose at least 4 weeks after the second to immunocompromised individuals 18 years of age and older.
    • provide a single booster dose for individuals 18 years of age and older at least five months after completing a primary series of the vaccine.
    • provide a second booster dose to individuals 50 years of age and older at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine.
    • provide a second booster dose of the Moderna COVID-19 Vaccine may be administered at least 4 months after the first booster dose of any authorized or approved COVID-19 vaccine to individuals 18 years of age and older with with certain kinds of immunocompromise. These are people who have undergone solid organ transplantation, or who are living with conditions that are considered to have an equivalent level of immunocompromise.

Additionally, the Johnson & Johnson/Janssen COVID-19 vaccine remains available under an Emergency Use Authorization (EUA) status.

The CDC recommends that everyone ages 5 years and older get their primary series of COVID-19 vaccine. Everyone ages 12 years and older is recommended to get a booster shotExternal Link​  at 2 months after receiving a Johnson & Johnson/Janssen vaccine or at least 5 months after completing their Pfizer or Moderna COVID-19 vaccine primary series. Teens 12-17 years old can only get a Pfizer-BioNTech COVID-19 va​ccine booster. For adults 18 years and older, a booster dose of either Pfizer-BioNTech or Moderna (mRNA COVID-19 vaccines) is preferred in most situations.​

Following FDA's regulatory actionExternal Link​, the CDC has updated its recommendations to allow certain immunocompromised individuals and people over the age of 50 who received an initial booster dose at least 4 months ago to be eligible for another mRNA booster to increase their protection against severe disease from COVID-19. Separately and in addition, based on newly published dataExternal Link, adults w​ho received a primary vaccine and booster dose of Johnson & Johnson's Janssen COVID-19 vaccine at least 4 months ago may now receive a second booster dose using an mRNA COVID-19 vaccine.​

Eligibility When Not Otherwise Mandated

All DoD beneficiaries and other individuals who are eligible to receive vaccines and booster doses from DoD will be offered and are encouraged to receive the COVID-19 immunization in accordance with recommendations from the Centers for Disease Control and Prevention (CDC) and its Advisory Committee on Immunization Practices (ACIP) and under the Food and Drug Administration (FDA) guidelines.


Military Health System (MHS) COVID-19 Vaccine Resource Center for Healthcare Personnel

Information and resources on the COVID-19 Vaccination Program from the Defense Health Agency Immunization Healthcare Division. This information is geared toward health care personnel in the DoD. Click here to learn moreExternal Link


Communication Products and Educational Resources

Announcements

 


 

Building Vaccine Confidence

  • Defense Health Agency COVID-19 Vaccine ToolkitExternal Link Use this digital toolkit to help you communicate with beneficiaries about the COVID-19 vaccine. The assorted print, digital, and social media graphics should be used locally to generate awareness among populations.

COVID-19 Products for Line Leadership from DHA


​File

​​Description

Line Leader Presentation PPTExternal Link


​Leaders across the Department can leverage this briefing deck to discuss COVID-19 vaccines with their troops. Don't forget to reference speaker notes and to personalize the title slide!

Line Leader Presentation (PDF)External Link

​This document is identical to the PowerPoint presentation for line leader reference and use.

Presentation CompanionExternal Link

​Leaders and public affairs officers may reference this document. It can be shared with commands to support briefings, or distributed independently to share facts about COVID-19 vaccines.

Reasons to Choose a COVID-19 Vaccine Fact SheetExternal Link

​Leaders and public affairs officers can share this information across channels to continue the vaccine confidence conversation.




Pre-vaccination



Vaccination



Vaccine Safety

DoD is confident in the stringent regulatory processes and requirements of the FDA. Manufacturers are required to submit their raw data for the FDA to review. Safety, immune response, and efficacy data from the trial stages are submitted to the FDA before the vaccines are authorized for use and distribution. Per FDA requirements, DoD will be monitoring and tracking reports of vaccine side effects through various surveillance activities both internal and external to the DoD.  Click here to learn moreExternal Link


Post-vaccination


General Resources



CDC SYNDICATED CONTENT

If you do not see CDC content below, click hereExternal Link or try a different browser.